WEGOVY® FLEXTOUCH® 0.5mg (Italian)

Description

Name: WEGOVY® FLEXTOUCH® 0.5mg (Italian)
Manufacturer: NOVO NORDISK
Active Substance(s): SEMAGLUTIDE
Strength: 0.5mg
Pack Size: 1 Pen, 4 disposable NovoFine Plus needles

WEGOVY® FLEXTOUCH® 0.5mg is a once-weekly, pre-filled injectable pen containing semaglutide, a GLP-1 receptor agonist indicated for chronic weight management. It is used during weeks 5–8 of the dose-escalation schedule and plays a critical role in patient titration to higher therapeutic levels, ultimately reaching 2.4mg.

• Designed for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity

• Acts by regulating appetite, increasing satiety, and reducing caloric intake

• Provides a stepping dose between the 0.25mg initiation dose and higher maintenance doses

Key Features:

• Active ingredient: 0.5mg semaglutide per 0.5mL solution

• Once-weekly dosing with consistent plasma levels and high patient adherence

• Reduces body weight, waist circumference, and cardiometabolic risk factors

WEGOVY® FLEXTOUCH® 0.5mg is packaged in a single-use, pre-filled FlexTouch® pen designed for subcutaneous injection. The pen is color-coded and labeled for easy identification by patients and healthcare professionals during the titration process.

Each pen contains:

• 0.5mL of solution delivering 0.5mg semaglutide

• One dose per pen, with no need for dose calculation or manipulation

• 5 pens per pack, covering 5 weeks of therapy if used weekly

Composition per 0.5mL:

• Semaglutide 0.5mg

• Disodium phosphate dihydrate

• Sodium chloride

• Hydrochloric acid/sodium hydroxide (for pH adjustment)

• Water for injections

WEGOVY® 0.5mg is indicated as part of a chronic weight management protocol, used in combination with reduced-calorie diet and increased physical activity. This dose is not for long-term maintenance but is a critical step in the gradual up-titration of semaglutide.

Indicated for:

• Adults with a BMI ≥30 kg/m²

• Adults with BMI ≥27 kg/m² with at least one comorbidity (e.g., type 2 diabetes, hypertension, dyslipidemia)

Contraindications:

• Hypersensitivity to semaglutide or excipients

• Personal/family history of medullary thyroid carcinoma (MTC)

• Multiple endocrine neoplasia syndrome type 2 (MEN 2)

• Pregnancy or breastfeeding

Common Side Effects:

• Gastrointestinal disorders (nausea, vomiting, diarrhea, constipation)

• Headache, fatigue, dizziness

• Injection site reactions

Less Common/Serious Effects:

• Pancreatitis

• Gallbladder disorders (e.g., cholelithiasis)

• Hypoglycemia (especially in patients on insulin or sulfonylureas)

WEGOVY® 0.5mg is administered via subcutaneous injection once weekly. The injection can be given in the abdomen, thigh, or upper arm, and should be performed on the same day each week, at any time of day, with or without food.

Administration Guidelines:

• No dose adjustment necessary for age, gender, race, or renal/hepatic function

• Patients must complete 4 weeks of 0.25mg dosing before initiating 0.5mg

• After 4 weeks at 0.5mg, patients titrate up to 1.0mg, 1.7mg, and then 2.4mg

• Use each pen only once; discard after use even if residual solution remains

Storage Instructions:

• Unopened pens: Store in refrigerator at 2°C–8°C

• After removal from the fridge: may be stored at up to 30°C for up to 6 weeks

• Do not freeze; discard if accidentally frozen

• Protect from light; keep in original packaging

Warning! The product is intended solely for professional use in a medical environment and under professional supervision. The product is supplied to medical professionals who specialize in aesthetic medicine (plastic surgery, facial treatments) and work under individual medical licenses as aestheticians or in dedicated clinics. Unprofessional use by individuals without a medical background may lead to severe adverse effects and health harm.